Accueil   Diary - News   All news Tollys presents scientific data for TL-532, its cancer immunotherapy drug candidate

Tollys presents scientific data for TL-532, its cancer immunotherapy drug candidate

Tollys presents scientific data supporting preclinical proof of concept for TL-532, its cancer immunotherapy drug candidate

 

Lyon, France, June 7, 2021 — Tollys, a biopharmaceutical company developing TL-532, the first synthetic specific agonist of Toll-like Receptor 3 (TLR3) cancer immunotherapy, today announces the presentation of a number of scientific results showing a preclinical proof of concept for TL-532 in the treatment of multiple cancers; at two online scientific conferences.

 

Read the press release